NASDAQ:DMTX Dimension Therapeutics (DMTX) Stock Price, News & Analysis → Just Released: Insider's Secret to Trading Options (From Schaeffer’s Research) (Ad) Free DMTX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range$5.95▼$5.9550-Day Range N/A52-Week Range$1.05▼$6.10VolumeN/AAverage Volume150,214 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Dimension Therapeutics alerts: Email Address Ad WealthPressThe system that called 2023’s top 7 stocks is at it again…Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.Just follow this link here! About Dimension Therapeutics Stock (NASDAQ:DMTX)Dimension Therapeutics, Inc. is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa). The Company's gene therapy product candidates and programs are designed to provide a functional copy of an abnormal or missing gene using the advanced adeno-associated virus (AAV)-based vector delivery technology. DTX101 is the Company's lead gene therapy product candidate designed to deliver Factor IX (FIX), gene expression in patients with hemophilia B. DTX201 is its Factor VIII (FVIII) gene therapy program for the treatment of hemophilia A. DTX301 is its gene therapy product candidate designed for the treatment of patients with OTC deficiency. DTX401 is its gene therapy program for the treatment of patients with GSDIa.Read More Ad WealthPressThe system that called 2023’s top 7 stocks is at it again…Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.Just follow this link here! DMTX Stock News HeadlinesApril 23, 2024 | yahoo.comPlay Mahjongg Dark Dimensions Online for Free | Yahoo! GamesMarch 18, 2024 | yahoo.comPlay Mahjong Dimensions Online for Free | Yahoo! GamesApril 25, 2024 | The TradingPub (Ad)At first glance, this chart looks like nonsense…We can isolate the most bullish dates to buy Netflix each and every year… That’s why one former hedge fund manager calls these dates… “Hotspot Dates”December 11, 2023 | news.bbc.co.ukPitch dimensionsJuly 26, 2023 | bbc.co.ukRussia warns of 'new dimension' in Ukraine warMay 25, 2023 | finance.yahoo.comKAYS - Kaya Holdings, Inc.March 11, 2023 | seekingalpha.comNano Dimension offers to acquire Stratasys for $18 a share (update)January 12, 2023 | msn.comAnime Dimensions Codes (January 2023)April 25, 2024 | The TradingPub (Ad)At first glance, this chart looks like nonsense…We can isolate the most bullish dates to buy Netflix each and every year… That’s why one former hedge fund manager calls these dates… “Hotspot Dates”January 5, 2023 | msn.comStartup Trying to Test Whether People on DMT Experience a Shared Alien UniverseSeptember 24, 2022 | finance.yahoo.comMETAVERSE ARTISTS PSYONICS HAVE MUST-SEE PERFORMANCE IN VIRTUAL LIVE ENTERTAINMENT PLATFORM VRJAM'S "5TH DIMENSION"September 22, 2022 | finance.yahoo.comUnlimited Dimension DODOOR NFTs ExplainedJune 8, 2022 | marketwatch.comGlobal Duchenne Muscular Dystrophy (DMD) Therapeutics Market 2022 Size, Share, Applications, Advance Technology and Top Companies to 2028See More Headlines Receive DMTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dimension Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/06/2017Today4/25/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNASDAQ:DMTX CUSIPN/A CIK1592288 Webdimensiontx.com Phone+1-617-4010011FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesGeorges Gemayel Ph.D. (Age 56)Chairman of the Board Annalisa M. Jenkins (Age 52)President, Chief Executive Officer, Director Mary T. Thistle (Age 57)Principal Financial and Accounting Officer, Chief Operating Officer Samuel C. Wadsworth Ph.D. (Age 68)Chief Scientific Officer Eric Crombez M.D. (Age 44)Chief Medical Officer John Hohneker (Age 57)Director Alan B. Colowick M.D. (Age 54)Independent Director Michael Dybbs Ph.D. (Age 42)Independent Director George V. Migausky (Age 62)Independent Director Arlene M. Morris (Age 65)Independent Director More Executives DMTX Stock Analysis - Frequently Asked Questions How were Dimension Therapeutics' earnings last quarter? Dimension Therapeutics, Inc. (NASDAQ:DMTX) released its quarterly earnings data on Monday, November, 6th. The biotechnology company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.48) by $0.20. The biotechnology company earned $4.48 million during the quarter. What other stocks do shareholders of Dimension Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Dimension Therapeutics investors own include Corbus Pharmaceuticals (CRBP), Cross Timbers Royalty Trust (CRT), Innovative Industrial Properties (IIPR), Palatin Technologies (PTN), Aldeyra Therapeutics (ALDX), Allena Pharmaceuticals (ALNA), Ampliphi Biosciences (APHB), Aquinox Pharmaceuticals (AQXP), Ardelyx (ARDX) and Atara Biotherapeutics (ATRA). This page (NASDAQ:DMTX) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry Research1970’s computer coder issues shocking A.I. warningTradeSmithExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dimension Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
